FDA clears bioMérieux BIOFIRE SPOTFIRE Vaginitis Panel for rapid point-of-care molecular testing

New 20-minute molecular test brings rapid identification of common causes of vaginitis directly to the point-of-care

23 Oct 2026
biomerieux logo

Summary: bioMérieux has received FDA 510(k) clearance and a CLIA waiver for the BIOFIRE SPOTFIRE Vaginitis (VG) Panel, a rapid multiplex PCR test designed to identify common causes of vaginitis at the point of care. The automated test reports eight results from a single vaginal swab in about 20 minutes, supporting diagnosis and treatment decisions within a typical patient visit. Compatible with both self-collected and clinician-collected swabs, the panel will be commercially available in the US from the beginning of 2027.


bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel has received Dual 510(k) Clearance and CLIA Waiver* from the U.S. Food and Drug Administration (FDA). This automated, multiplex polymerase chain reaction (PCR) test can simultaneously detect the most common causes of vaginitis in about 20 minutes, directly at the point of care on the BIOFIRE® SPOTFIRE® System, bringing rapid and accurate diagnostics closer to patients.

Most women will experience an episode of vaginitis during their lifetime, often associated with a range of painful symptoms1. Vaginitis is a broad clinical term encompassing conditions such as bacterial vaginosis, vulvovaginal candidiasis, or trichomoniasis, which may arise from an imbalance of the microbiome or infection. Despite its high prevalence, vaginitis is often misdiagnosed or incompletely characterized using traditional methods that are subjective or may lack sensitivity. Only about half of women diagnosed with vaginitis by non-molecular testing receive appropriate treatment2.

Results in a typical patient visit

The BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel is the first rapid molecular vaginitis test and aims to support timely treatment decisions and deliver a clear and accurate diagnostic experience, which is associated with overall improved patient management2. The BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel reports 8 results with one swab, including bacterial vaginosis, yeast, and parasite pathogens,3 in about 20 minutes, to align with a typical patient visit. The BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel can be run with both self-collected and clinician-collected vaginal swabs, providing flexible options to address the unique needs of different patients and healthcare settings. This approach enables healthcare professionals to deliver rapid results and make treatment decisions during a patient visit.

“Not only are the symptoms of vaginitis disruptive and painful, but the underlying condition is also associated with other health conditions, including pelvic inflammatory disease, cervical cancer, adverse birth outcomes, and secondary infections. bioMérieux is proud to bring a better diagnostic solution to patients, which can guide healthcare practitioners in prescribing targeted treatment to more quickly alleviate symptoms and potentially reduce the risk of other negative health consequences,” stated Dr. Charles K. Cooper, Executive Vice President, Chief Medical Officer, bioMérieux.

“Today, there is a clear and persistent gap in vaginitis diagnostics — between the need for accurate, comprehensive testing and the reality of delayed or incomplete results in clinical practice. With the FDA clearance of the BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel, bioMérieux is addressing this gap by bringing fast, syndromic molecular testing directly to the point-of-care setting, enabling healthcare practitioners to move from uncertainty to actionable answers within a single patient visit. This is not just an incremental improvement, it’s a strategic step toward closing a long-standing diagnostics gap in women’s health, fundamentally improving both clinical decision-making and the patient experience,” added Jennifer Zinn, Executive Vice President, Clinical Operations, at bioMérieux.

Expanding bioMérieux’s point-of-care offering

The BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel represents a meaningful expansion of bioMérieux’s innovative point-of-care portfolio, which already includes panels for respiratory and sore throat infections on the BIOFIRE® SPOTFIRE® System. The system is an easy-to-use, modular instrument with a small footprint designed to fit in any healthcare setting, including family care practices, urgent care settings, and obstetrician/gynecologist (OB/GYN) offices.

The BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel will be commercially available at the beginning of 2027 in the United States, followed by an extended rollout worldwide.

* Clinical Laboratory Improvement Amendments (CLIA) waiver allows the BIOFIRE® SPOTFIRE® Vaginitis Panel to be used by non-lab professionals at the point of care.


1. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1. Erratum in: MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):107-108. doi: 10.15585/mmwr.mm7204a5. PMID: 34292926; PMCID: PMC8344968.

2. Hillier SL, Macio I, Gallagher R, Meyn L, Beamer M, Zamborsky T, Campbell T, Bunge K, Wiesenfeld HC. Randomized Study of Usual Care vs Xpert® Xpress MVP at the Point of Care for Accurate Diagnosis and Appropriate Treatment of Vaginal Infections. Sex Transm Dis. 2026 May 12. doi: 10.1097/OLQ.0000000000002343. Epub ahead of print. PMID: 42117698.

3.Bacteria: Bacterial vaginosis - Result informed by an algorithm which assesses the relative abundance of multiple bacteria to provide a binary result. Organisms included are Fannyhessea (Atopobium) vaginae, Bacterial Vaginosis-Associated Bacterium 2 (BVAB2), Lactobacillus crispatus, Lactobacillus gasseri/paragasseri, Lactobacillus jensenii/mulieris, Sneathia sanguinegens/vaginalis (amnii) Yeast: Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida dubliniensis Parasite: Trichomonas vaginalis

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

BIOFIRE® SPOTFIRE® System

bioMérieux

Respiratory diagnosis without the guesswork, offering the flexibility to choose either respiratory or sore throat testing based on the patient's signs and symptoms, delivering comprehensive results in about 15 minutes.

(0)

Links

Tags

Point-of-CarePoint-of-Care Testing (POCT) or Near Patient Testing (NPT) products are available for urine, blood and other clinical chemistry analyses. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing (PT / INR), rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.Womens HealthPoint of Care SolutionsPoint of care solutions provide medical diagnostics and treatments at or near the site of patient care. These technologies offer rapid results, helping healthcare providers make quick decisions. From glucose monitors to molecular diagnostics, point of care solutions are transforming healthcare delivery by reducing wait times and improving patient outcomes. Explore the best point of care products in our peer-reviewed product directory, compare options, check reviews, and get pricing directly from manufacturers.Molecular DiagnosticsMolecular diagnostics use an individual’s genetic code and gene expression to diagnose and monitor diseases. The technique is used increasingly in the field of infectious diseases and oncology, as well as areas such as coagulation, HLA typing and pharmacogenomics. Molecular diagnostics plays a pivotal role in personalized medicine.

Frequently asked questions

Show frequently asked questions

What is the BIOFIRE SPOTFIRE Vaginitis Panel?

The BIOFIRE SPOTFIRE Vaginitis (VG) Panel is an automated multiplex PCR test from bioMérieux designed to detect common causes of vaginitis at the point of care.

What does the BIOFIRE SPOTFIRE Vaginitis Panel test for?

The panel reports eight results from a single vaginal swab, covering bacterial vaginosis, yeast and parasite pathogens associated with vaginitis.

How quickly does the BIOFIRE SPOTFIRE Vaginitis Panel provide results?

The test provides results in approximately 20 minutes, allowing testing and treatment decisions to take place during a typical patient visit.

Is the BIOFIRE SPOTFIRE Vaginitis Panel FDA cleared?

Yes. bioMérieux has received FDA 510(k) clearance and a CLIA waiver for the BIOFIRE SPOTFIRE Vaginitis (VG) Panel.

Can patients self-collect samples for the BIOFIRE SPOTFIRE Vaginitis Panel?

Yes. The panel can be used with both self-collected and clinician-collected vaginal swabs, providing flexibility for different patients and healthcare settings.

Where can the BIOFIRE SPOTFIRE Vaginitis Panel be used?

The BIOFIRE SPOTFIRE System is designed for point-of-care environments including family care practices, urgent care settings and obstetrician/gynecologist (OB/GYN) offices.

When will the BIOFIRE SPOTFIRE Vaginitis Panel be available?

bioMérieux plans to make the panel commercially available in the United States at the beginning of 2027, followed by a wider international rollout.